Abstract:Introduction Depression represents a significant challenge in terms of disability among the elderly population and its responsiveness to conventional treatment approaches tends to diminish in this population group. Esketamine has shown both effectiveness and safety in addressing treatment-resistant depression in older patients. Objectives Currently, there is a lack of available literature regarding the use of esketamine in the treatment of patients experiencing both cognitive decline and treatment-resistant depression (TRD). We administered esketamine to a 79-year- old patient to evaluate the effectiveness and tolerance of the medication. Methods We recruited a 79 year old female referred to the outpatient clinics of Pavia suffering from TRD with current Severe Depressive Episode (scoring 42 on the MADRS) with cognitive impairment (MMSE 16/30). The patient was on a fourth-line treatment. First-line treatment was started with paroxetine 40 mg from september 2021 to May 2022, switched to sertraline 50 mg. Second-line treatment with quetiapine 150 mg from June 2022 to December 2022 failed, despite optimal compliance for both lines of treatment. Then third line treatment with fluoxetine 20 mg, olanzapine 10 mg was initiated from December 2022 to May 2023. Study duration was 12 weeks. Anamnestic data and psychometric (MADRS, HAMD-21, HAM-A) and cognitive (MMSE and MoCA TEST) assessment were collected from medical records at baseline (T0), one month (T1) and three month (T2) follow-ups. Results MADRS, HAM-A and HAM-D values decreased significantly at T1 and T2 follow-ups. T0: MADRS 42, HAM-D 33, HAM-A 54; T1: MADRS 18, HAM-D 12, HAM-A 15; T2: MADRS 4, HAM-D 5, HAM-A 10. We also observed an improvement in cognitive test: T0: MMSE 16/30, MoCA test 4/30; T1: MMSE 18/30, MoCA test 6/30; T2: MMSE 20/30, MoCA test 8/30. The patient reported one episode of hypertension treated with clonidine after two moth of treatment, and mild prolonged motor slowing lasting about two hours after esketamine in the first month. Conclusions This case documented a successful treatment using intranasal esketamine in combination with an SSRI (Fluoxetine) for an older individual with cognitive impairment and a persistent anxiety-depressive syndrome. This approach was employed as a therapeutic intervention after multiple unsuccessful attempts with other antidepressant medications. Our findings confirmed the safety and tolerability of esketamine in an elderly female with cognitive impairment. Although a minor improvement in cognitive abilities has been noted, secondary dysfunction attributable to vascular-based cognitive decline remained. In terms of cognitive tolerance, derivatives of ketamine could potentially serve as an alternative to electroconvulsive therapy in cases of treatment-resistant depression, potentially improving short-term cognitive outcomes. Disclosure of Interest None Declared

Add-on quetiapine in the treatment of major depressive disorder in elderly patients with cerebrovascular damage

Efficacy and safety of quetiapine augmentation of antidepressants on depression

A comparative study of quetiapine and risperidone in treatment of mental disorders due to vascular disease in the advanced elderly

Quetiapine Attenuates the Depressive and Anxiolytic-Like Behavioural Changes Induced by Global Cerebral Ischemia in Mice

Quetiapine attenuates spatial memory impairment and hippocampal neurodegeneration induced by bilateral common carotid artery occlusion in mice.

Quetiapine Prevents Oligodendrocyte and Myelin Loss and Promotes Maturation of Oligodendrocyte Progenitors in the Hippocampus of Global Cerebral Ischemia Mice

Quetiapine add-on therapy improves the depressive behaviors and hippocampal neurogenesis in fluoxetine treatment resistant depressive rats.

Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study

Efficacy of Repetitive Transcranial Magnetic Stimulation with Quetiapine in Treating Bipolar II Depression: a Randomized, Double-Blinded, Control Study

Long-term quetiapine therapy on the cognitive function in patients with Alzheimer's disease

Efficacy and Safety of Quetiapine-Xr As Monotherapy or Adjunctive Therapy to a Mood Stabilizer in Acute Bipolar Depression with Generalized Anxiety Disorder and Other Comorbidities: a Randomized, Placebo-Controlled Trial.

Can Quetiapine Prolong the Antidepressant Effect of Ketamine?: A 5-Year Follow-up Study

Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response—a prospective open-label study

[Repetitive Transcranial Magnetic Stimulation Combined with Antidepressant Medication in Treatment of First-Episode Patients with Major Depression].

The Therapeutic Effect of Quetiapine on Cognitive Impairment Associated with 5-HT1A Presynaptic Receptor Involved Schizophrenia

EFFECT OF PAROXETINE COMBINED WITH QUETIAPINE IN THE TREATMENT OF DEPRESSION WITH PHYSICAL SYMPTOMS

Efficacy of Once-Daily Extended Release Quetiapine Fumarate Across Symptom Domains in Schizophrenia

Esketamine for resistant depression in older people with cognitive impairment: a case report

Effects of Quetiapine-Augmentation on Clinical Symptom and Cognitive Functioning in Obsessive-Compulsive Disorder

A Comparative Study of Quetiapine in the Treatment of Elderly Brain Organic Mental Disorders

Citalopram in the treatment of elderly chronic heart failure combined with depression: A systematic review and meta-analysis